What is the use of Methylene blue?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Methylene blue is the primary treatment for decreasing methemoglobin levels, and it should be administered at a starting dose of 1–2 mg/kg intravenously over 3 to 5 minutes. This recommendation is based on the most recent and highest quality study available, which was published in the American Journal of Hematology in 2021 1. The study highlights the importance of methylene blue in treating methemoglobinemia, a condition where blood cannot effectively carry oxygen.

Key Points to Consider

  • The dose of methylene blue may be repeated at 1 mg/kg if methemoglobinemia does not significantly decrease within 30–60 minutes 1.
  • However, it is crucial to note that the risk of worsening of methemoglobinemia increases with repeated doses, with toxic levels of methylene blue reached at a total dose > 7 mg/kg 1.
  • In cases of worsening methemoglobinemia after methylene blue treatment, urgent exchange transfusion should be performed 1.
  • For patients with continued production of methemoglobin from a long-acting oxidant stress, such as after dapsone ingestion, repeat dosing every 6–8 hours for up to 2–3 days or a continuous IV infusion of 0.10–0.25 mg/kg/hr may be necessary 1.

Important Considerations for Treatment

  • Methylene blue should reduce methemoglobin levels significantly in less than an hour 1.
  • A rebound phenomenon of increased methemoglobin levels after completion of therapy is attributed to the reversal of the reduction reaction 1.
  • The medication works by accepting an electron from NADPH and reducing the 3+ ferric state back to the 2+ ferrous state in erythrocytes 1.

From the Research

Methylene Blue Uses

  • Methylene blue is used to treat methemoglobinemia at a dose of 1 to 2 mg/kg intravenously 2
  • It is also used as a treatment for ifosfamide-induced encephalopathy, with some studies showing its effectiveness in preventing or reversing the condition 3, 4, 5
  • Additionally, methylene blue has been used to treat refractory vasoplegic shock in both pediatric and adult critical care patients 5
  • It has also been proposed as a potential adjunct in the treatment of septic shock, anaphylactic shock, and toxin-induced shock 6

Methylene Blue Mechanism of Action

  • Methylene blue's mechanism of action is based partly on its oxidizing capabilities, which can help reduce methemoglobin to hemoglobin 2, 5
  • It can also interfere with guanylate cyclase activity, preventing cyclic guanosine monophosphate production and vasodilatation, which can help increase blood pressure in shock states 6

Methylene Blue Administration and Dosage

  • Methylene blue can be administered intravenously, with dosages ranging from 1 to 2 mg/kg for methemoglobinemia treatment 2
  • For ifosfamide-induced encephalopathy, methylene blue has been administered at a dose of 50 mg intravenously every 6 hours 3
  • The optimal dosage and administration schedule for methylene blue in other conditions, such as shock states, may vary and require further study 6

Methylene Blue Side Effects and Risks

  • Methylene blue can cause dose-related hemolytic effects, and people with G-6-PD deficiency may be at special risk 2
  • Serotonergic syndrome is also a potential side effect of methylene blue treatment, particularly when used in combination with other medications 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Methylene blue.

American journal of therapeutics, 2003

Research

Hydration, methylene blue, and thiamine as a prevention regimen for ifosfamide-induced encephalopathy.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2019

Research

Methylene blue and ifosfamide-induced encephalopathy: Myth or reality?

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021

Research

A review of methylene blue treatment for cardiovascular collapse.

The Journal of emergency medicine, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.